Prehospital Emergency Medical Services, Central Denmark Region, Aarhus.
Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark.
JAMA. 2021 Dec 14;326(22):2268-2276. doi: 10.1001/jama.2021.20929.
It is unclear whether administration of calcium has a beneficial effect in patients with cardiac arrest.
To determine whether administration of calcium during out-of-hospital cardiac arrest improves return of spontaneous circulation in adults.
DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial included 397 adult patients with out-of-hospital cardiac arrest and was conducted in the Central Denmark Region between January 20, 2020, and April 15, 2021. The last 90-day follow-up was on July 15, 2021.
The intervention consisted of up to 2 intravenous or intraosseous doses with 5 mmol of calcium chloride (n = 197) or saline (n = 200). The first dose was administered immediately after the first dose of epinephrine.
The primary outcome was sustained return of spontaneous circulation. The secondary outcomes included survival and a favorable neurological outcome (modified Rankin Scale score of 0-3) at 30 days and 90 days.
Based on a planned interim analysis of 383 patients, the steering committee stopped the trial early due to concerns about harm in the calcium group. Of 397 adult patients randomized, 391 were included in the analyses (193 in the calcium group and 198 in the saline group; mean age, 68 [SD, 14] years; 114 [29%] were female). There was no loss to follow-up. There were 37 patients (19%) in the calcium group who had sustained return of spontaneous circulation compared with 53 patients (27%) in the saline group (risk ratio, 0.72 [95% CI, 0.49 to 1.03]; risk difference, -7.6% [95% CI, -16% to 0.8%]; P = .09). At 30 days, 10 patients (5.2%) in the calcium group and 18 patients (9.1%) in the saline group were alive (risk ratio, 0.57 [95% CI, 0.27 to 1.18]; risk difference, -3.9% [95% CI, -9.4% to 1.3%]; P = .17). A favorable neurological outcome at 30 days was observed in 7 patients (3.6%) in the calcium group and in 15 patients (7.6%) in the saline group (risk ratio, 0.48 [95% CI, 0.20 to 1.12]; risk difference, -4.0% [95% CI, -8.9% to 0.7%]; P = .12). Among the patients with calcium values measured who had return of spontaneous circulation, 26 (74%) in the calcium group and 1 (2%) in the saline group had hypercalcemia.
Among adults with out-of-hospital cardiac arrest, treatment with intravenous or intraosseous calcium compared with saline did not significantly improve sustained return of spontaneous circulation. These results do not support the administration of calcium during out-of-hospital cardiac arrest in adults.
ClinicalTrials.gov Identifier: NCT04153435.
目前尚不清楚在心脏骤停患者中应用钙剂是否有益。
明确在院外心脏骤停患者中应用钙剂是否能改善成人自主循环恢复。
设计、地点和参与者:这是一项双盲、安慰剂对照的随机临床试验,纳入了 397 例院外心脏骤停的成年患者,在 2020 年 1 月 20 日至 2021 年 4 月 15 日期间在丹麦中部地区进行。最后一次 90 天随访是在 2021 年 7 月 15 日。
干预组包括最多 2 次静脉或骨内给予 5mmol 氯化钙(n = 197)或生理盐水(n = 200)。首次剂量在首次肾上腺素给药后立即给予。
主要结局是持续自主循环恢复。次要结局包括 30 天和 90 天的存活率和良好的神经功能结局(改良 Rankin 量表评分为 0-3)。
基于对 383 例患者的计划中期分析,由于担心钙组存在危害,指导委员会提前停止了试验。397 例成年患者随机分组,391 例患者纳入分析(钙组 193 例,生理盐水组 198 例;平均年龄 68 [标准差 14]岁;114 例[29%]为女性)。无失访。钙组有 37 例(19%)患者发生持续自主循环恢复,生理盐水组有 53 例(27%)患者发生持续自主循环恢复(风险比 0.72 [95%CI 0.49 至 1.03];风险差 -7.6% [95%CI -16% 至 0.8%];P = 0.09)。30 天时,钙组有 10 例(5.2%)患者存活,生理盐水组有 18 例(9.1%)患者存活(风险比 0.57 [95%CI 0.27 至 1.18];风险差 -3.9% [95%CI -9.4% 至 1.3%];P = 0.17)。钙组有 7 例(3.6%)患者在 30 天时神经功能良好,生理盐水组有 15 例(7.6%)患者神经功能良好(风险比 0.48 [95%CI 0.20 至 1.12];风险差 -4.0% [95%CI -8.9% 至 0.7%];P = 0.12)。在自主循环恢复的患者中测量钙值,钙组有 26 例(74%)患者发生高钙血症,生理盐水组有 1 例(2%)患者发生高钙血症。
在院外心脏骤停的成人中,与生理盐水相比,静脉或骨内给予钙剂并未显著改善自主循环恢复。这些结果不支持在成人院外心脏骤停中给予钙剂。
ClinicalTrials.gov 标识符:NCT04153435。